Abivax is growing revenue at 35% year-over-year with analyst consensus implying 52% upside to the price target, but cash burn running at -2,327% of revenue and a quality profile below the minimum quality threshold make this a high-risk, speculative situation where the growth must eventually translate into cash economics.
Thesis pillars
- Extreme Cash Burn Value Trap Risk→Stable
- Strong Revenue Growth 35pct→Stable
- Analyst Sentiment Material Upside↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026
Abivax SA (ABVX) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $87.00: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 7.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in... Read more
Sell if holding. Engine safety override at $87.00: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 7.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 50. Score 4.8/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 145d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated 2026-10-28Recent Developments — Abivax SA
Latest news
- NEWS 10 Health Care Stocks Whale Activity In Today’s Session — benzinga Oct 23, 2026 neutral
- NEWS Wedbush Maintains Neutral on Abivax, Lowers Price Target to $96 — benzinga Oct 21, 2026 negative
- NEWS Wedbush Adjusts Price Target on Abivax to $96 — fiscal.ai Oct 20, 2026 neutral
- NEWS Guggenheim Reiterates Buy on Abivax, Maintains $175 Price Target — benzinga Oct 20, 2026 positive
- NEWS 10 Health Care Stocks With Whale Alerts In Today’s Session — benzinga Oct 13, 2026 neutral
Generated 2026-10-28T12:03:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Revenue shrinking — -6.8% YoY. Growth thesis broken unless recovery story develops.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $87.00: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 7.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 50. Prior stop was $81.59. Score 4.8/10, moderate confidence.
Analyst target: $142.32 (+63.6% upside). Prior stop was $81.59. Stop-loss: $81.59.
Quality below floor (3.7 < 4.0).
Abivax SA trades at a P/E of N/A (forward -22.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
14 analysts cover ABVX with a consensus score of 4.2/5. Average price target: $164.
What does Abivax SA do?ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural...
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.